coin types crypto- Top Overview

Sixteen people have been sentenced for the anti-corruption storm in football. Since Li Tie, the former head coach of China Men's Football Team, was investigated in November 2022, a new round of anti-corruption storm has blown up in China football. The storm has become more and more fierce, involving not only players gambling and bribery at the top of the club, but also corrupt elements at the top of the Football Association and even the General Administration of Sports. Today, Li Tie's case and Du Zhaocai's case, the former vice chairman of the Chinese Football Association, were pronounced in the first instance. Up to now, 16 people have been sentenced in China football (Beijing Daily)China International Economic Exchange Center held the annual economic conference in China on December 14th, attended by Han Wenxiu of China Finance Office, and the annual economic conference in China on December 14th, with the theme of implementing the spirit of the Central Economic Work Conference and promoting sustained economic recovery. Han Wenxiu from Zhongcai Office, Zhao Chenxin, Deputy Director of National Development and Reform Commission, Sheng Qiuping, Vice Minister of Commerce, and Wang xin, Director of Research Bureau of China People's Bank will give keynote speeches. (China International Economic Exchange Center)As a result of providing loans with private fund property, Haisi Quanzong's private placement and responsible person were supervised to issue a warning letter. On December 13th, Qingdao Securities Regulatory Bureau issued a notice saying that after investigation, Qingdao Haisi Quanzong Private Fund Management Co., Ltd. (hereinafter referred to as "Haisi Quanzong Private Placement") provided loans with private fund property, which violated the regulations. Song Xiuhong was then the legal representative and chairman of Haisi Quanzong Private Equity, and Liu Jialiang is now the legal representative and chairman of Haisi Quanzong Private Equity. Since the establishment of Haisi Quanzong Private Equity, Wang Zhaohui has been the general manager. During his tenure, he failed to fulfill his duties and strictly abide by laws and regulations, and was responsible for the above acts. Qingdao Securities Regulatory Bureau took administrative supervision measures to issue warning letters to Haisi Quanzong Private Equity, Song Xiuhong, Liu Jialiang and Wang Chaohui.

Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.Xinxiangwei: Shareholder Xinyu Yijiade intends to reduce its shareholding by no more than 1%. Xinxiangwei announced that as of the disclosure date, Shareholder Xinyu Yijiade holds 20,175,800 shares of the company, accounting for 4.39% of the company's total share capital. Xinyu Yijiade plans to reduce the number of shares of the company by no more than 4,595,300 shares through centralized bidding or block trading of Shanghai Stock Exchange within 90 days after 15 trading days from the date of announcement, and the proportion of reduced shares in the company's total share capital is no more than 1%.The Baltic dry bulk freight index fell 0.38% to 1051 points.

Huangshan Capsule: It is planned to distribute a cash dividend of 0.27 yuan for every 10 shares. Huangshan Capsule announced that the company held the board of directors and the board of supervisors on December 13, 2024, and reviewed and approved the profit distribution plan for the first three quarters of 2024. According to the plan, the company plans to distribute a cash dividend of RMB27 to all shareholders for every 10 shares based on the existing total share capital of 299 million shares, with a total cash dividend of RMB8,075,700. This profit distribution will not send bonus shares, and capital reserve will not be converted into share capital.Donghua Technology: Inner Mongolia New Materials, a holding subsidiary, signed a product sales contract with Yulin Chemical of Shaanxi Coal Group. Donghua Technology announced that China National Chemical New Materials Co., Ltd., a holding subsidiary, plans to sign a Product Sales Contract with Yulin Chemical Co., Ltd. of Shaanxi Coal Group, stipulating that Yulin Chemical will sell ethylene glycol and by-products produced by Inner Mongolia New Materials. The contract is from October 20, 2024 to December 31, 2025. Product prices are divided into temporary pricing and settlement price, and are priced according to the principle of marketization. From the beginning of 2024 to the disclosure date, the Company had related transactions with Yulin Chemical and its concerted parties, mainly to provide engineering services to Yulin Chemical and its concerted parties, with the related transactions amounting to 438 million yuan.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.